Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by the Centre for Reviews and Dissemination, University of York.

  • Burch J, Paulden M, Conti S et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation, July 2008.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Organisations listed in I and II were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I) Manufacturers/sponsors:

  • Alliance Pharmaceuticals (amantadine)

  • GlaxoSmithKline (zanamivir)

  • Roche Products (oseltamivir)

II) Professional/specialist and patient/carer groups:

  • Diabetes UK

  • British Paediatric Respiratory Society

  • British Thoracic Society

  • Health Protection Agency

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Paediatrics and Child Health

  • Royal College of Pathologists

  • Royal College of Physicians

  • Royal Pharmaceutical Society

III) Other consultees

  • Cornwall and the Isles of Scilly Primary Care Trust

  • Department of Health

  • Dudley Primary Care Trust

  • Welsh Assembly Government

IV) Commentator organisations (did not provide written evidence and without the right of appeal)

  • British National Formulary

  • Cancer Care Cymru

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Welsh Kidney Patients Association

  • NHS Centre for Reviews and Dissemination and Centre for Health Economics, York

  • National Coordinating Centre for Health Technology Assessment

C. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance TA 58) by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Will Carroll, Consultant Paediatrician, nominated by the British Paediatric Respiratory Society Research Committee – clinical specialist

  • Dr Wei Shen Lim, Consultant Respiratory Physician, nominated by the Health Protection Agency – clinical specialist

  • Dr Maria Zambon, Clinical Expert, nominated by the Health Protection Agency – clinical specialist

  • National Institute for Health and Care Excellence (NICE)